ClearPoint Neuro, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ClearPoint Neuro, Inc. (CLPT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.10 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-03-12
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.10.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.00.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $2.55, a 722.58% increase year-over-year.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.31, a 69.31% decline year-over-year.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.10, a 25.76% decline from fiscal 2022.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $10.91, a 39.69% decline from fiscal 2021.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $18.09, a 316.82% increase from fiscal 2020.
- ClearPoint Neuro, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $4.34, a 26.16% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $8.10 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $8.10 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $8.10 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $8.10 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $10.91 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | $10.91 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $10.91 10-Q · filed 2022-08-10 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $18.09 10-K · filed 2022-03-09 | ||||
| 2021-09-30 | $18.12 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $20.61 10-Q · filed 2021-08-12 | ||||
| 2020-12-31 | $4.34 10-K · filed 2021-03-22 | ||||
| 2020-09-30 | $4.34 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $4.14 10-Q · filed 2020-08-13 | ||||
| 2019-12-31 | $3.44 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $3.34 10-Q · filed 2019-11-13 | ||||
| 2019-06-30 | $3.25 10-Q · filed 2019-08-12 | ||||
| 2018-12-31 | $1.81 10-K · filed 2020-03-27 | ||||
| 2018-09-30 | $1.81 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | $2.18 10-Q · filed 2018-08-14 | ||||
| 2017-12-31 | $2.58 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | $2.90 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $3.56 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | $2.55 10-Q · filed 2017-05-09 | ||||
| 2016-12-31 | $6.40 10-K · filed 2018-03-21 | ||||
| 2016-09-30 | $11.57 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | $11.57 10-Q/A · filed 2016-09-21 | ||||
| 2016-03-31 | $0.31 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | $32.80 10-K · filed 2017-03-09 | $0.82 10-K · filed 2016-03-25 | |||
| 2015-09-30 | $0.80 10-Q · filed 2015-11-13 | ||||
| 2015-06-30 | $1.04 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $1.01 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $1.09 10-K · filed 2016-03-25 | ||||
| 2014-09-30 | $1.05 10-Q · filed 2014-11-14 | ||||
| 2014-06-30 | $1.04 10-Q · filed 2014-08-11 | ||||
| 2014-03-31 | $1.40 10-Q · filed 2014-05-13 | ||||
| 2013-12-31 | $1.43 10-K · filed 2015-03-17 | ||||
| 2013-09-30 | $1.20 10-Q · filed 2013-11-13 | ||||
| 2013-06-30 | $1.14 10-Q · filed 2013-08-14 | ||||
| 2013-03-31 | $1.45 10-Q/A · filed 2013-08-19 | ||||
| 2012-12-31 | $1.08 10-K · filed 2014-03-28 | ||||
| 2012-09-30 | $1.02 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $1.00 10-Q · filed 2012-08-14 | ||||
| 2010-12-31 | $1.80 10-K/A · filed 2013-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |